Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia p...
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL).
We investigated whether expression ratios of immunoproteasome to constitutive proteasome in leukaemic cells corre...
Alternative Titles
Full title
Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_172eb78a2bea491c981a5e1211f1352f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_172eb78a2bea491c981a5e1211f1352f
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-016-0312-z
